Rational identification of an optimal antibody mixture for targeting the epidermal growth factor receptor

mAbs

Volumn 3, Issue 6, 2011, Pages

  Koefoed, Klaus ^a   Steinaa, Lucilla ^a,b   Søderberg, Josefine Nielsen ^a   Kjær, Ida ^a   Jacobsen, Helle Jane ^a   Meijer, Per Johan ^a,c   Haurum, John Sørensen ^a,d   Jensen, Allan ^a,e   Kragh, Michael ^a   Andersen, Peter Sejer ^a   Pedersen, Mikkel Wandahl ^a  

^a Symphogen AS   (Denmark)

^b INTERNATIONAL LIVESTOCK RESEARCH INSTITUTE   (Kenya)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d ELI LILLY AND COMPANY   (United States)

^e PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Antibody combinations; Antibody synergy; EGFR; Epitope binning; Functional screening

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPITOPE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 1024; MONOCLONAL ANTIBODY 1030; MONOCLONAL ANTIBODY 1260; MONOCLONAL ANTIBODY 1261; MONOCLONAL ANTIBODY 1277; MONOCLONAL ANTIBODY 1284; MONOCLONAL ANTIBODY 1320; MONOCLONAL ANTIBODY 1347; MONOCLONAL ANTIBODY 1565; MONOCLONAL ANTIBODY 992; PANITUMUMAB; SYM 004; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; SYM004 ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER INHIBITION; CROSS REACTION; DRUG EFFICACY; DRUG IDENTIFICATION; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PROTEIN DEGRADATION; PROTEIN TARGETING; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; DRUG SCREENING; EPITOPE MAPPING; GENETICS; IMMUNIZATION; IMMUNOLOGY; METABOLISM; NEOPLASM; SURFACE PLASMON RESONANCE; TREATMENT OUTCOME; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; EPITOPE MAPPING; EPITOPES; FEMALE; HUMANS; IMMUNIZATION; MICE; MICE, INBRED BALB C; NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURFACE PLASMON RESONANCE; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 81255210858     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.3.6.17955     Document Type: Article

References (39)

1. Bublil EM, Yarden Y. The EGF receptor family: spearheading a merger of signaling and therapeutics. Curr Opin Cell Biol 2007; 19:124-34. (Pubitemid 46386405)
2. Harris RC, Chung E, Coffey RJ. EGF receptor ligands. Exp Cell Res 2003; 284:2-13. (Pubitemid 36331964)
3. Ogiso H, Ishitani R, Nureki O, Fukai S, Yamanaka M, Kim JH, et al. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell 2002; 110:775-87. (Pubitemid 35291060)
4. Garrett TP, McKern NM, Lou M, Elleman TC, Adams TE, Lovrecz GO, et al. Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha. Cell 2002; 110:763-73. (Pubitemid 35283965)
5. Ferguson KM, Berger MB, Mendrola JM, Cho HS, Leahy DJ, Lemmon MA. EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. Mol Cell 2003; 11:507-17. (Pubitemid 36297057)
6. Wells A. EGF receptor. Int J Biochem Cell Biol 1999; 31:637-43. (Pubitemid 29248872)
7. Wells A, Gupta K, Chang P, Swindle S, Glading A, Shiraha H. Epidermal growth factor receptor-mediated motility in fibroblasts. Microsc Res Tech 1998; 43:395-411. (Pubitemid 28565787)
8. Huang Z, Brdlik C, Jin P, Shepard HM. A pan-HER approach for cancer therapy: background, current status and future development. Expert Opin Biol Ther 2009; 9:97-110.
9. Wong AJ, Ruppert JM, Bigner SH, Grzeschik CH, Humphrey PA, Bigner DS, et al. Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci USA 1992; 89:2965-9.
10. Damstrup L, Kuwada SK, Dempsey PJ, Brown CL, Hawkey CJ, Poulsen HS, et al. Amphiregulin acts as an autocrine growth factor in two human polarizing colon cancer lines that exhibit domain selective EGF receptor mitogenesis. Br J Cancer 1999; 80:1012-9. (Pubitemid 29233922)
11. Peghini PL, Iwamoto M, Raffeld M, Chen YJ, Goebel SU, Serrano J, et al. Overexpression of epidermal growth factor and hepatocyte growth factor receptors in a proportion of gastrinomas correlates with aggressive growth and lower curability. Clin Cancer Res 2002; 8:2273-85. (Pubitemid 34753601)
12. Arteaga CL. The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol 2001; 19:32-40.
13. Mendelsohn J, Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol 2006; 33:369-85. (Pubitemid 44142736)
14. Erbitux (cetuximab) Prescribing Information. Branchburg, NJ: ImClone Systems Inc., and Bristol-Myers Squibb 2010.
15. Vectibix (panitumumab) Prescribing Information. Thousand Oaks, CA: Amgen Inc. 2010.
16. Schmitz KR, Ferguson KM. Interaction of antibodies with ErbB receptor extracellular regions. Exp Cell Res 2009; 315:659-70.
17. van d, V, Oliveira S, Schiffelers RM, Storm G, van Bergen En Henegouwen PM, Roovers RC. Crosstalk between epidermal growth factor receptor- and insulin-like growth factor-1 receptor signaling: implications for cancer therapy. Curr Cancer Drug Targets 2009; 9:748-60.
18. Desbois-Mouthon C, Baron A, Blivet-Van Eggelpoel MJ, Fartoux L, Venot C, Bladt F, et al. Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/ HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma. Clin Cancer Res 2009; 15:5445-56.
19. Benavente S, Huang S, Armstrong EA, Chi A, Hsu KT, Wheeler DL, et al. Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells. Clin Cancer Res 2009; 15:1585-92.
20. Krumbach R, Schuler J, Hofmann M, Giesemann T, Fiebig HH, Beckers T. Primary resistance to cetuximab in a panel of patient-derived tumour xenograft models: Activation of MET as one mechanism for drug resistance. Eur J Cancer 2011; 47:1231-43.
21. Drebin JA, Link VC, Greene MI. Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo. Oncogene 1988; 2:387-94.
22. Friedman LM, Rinon A, Schechter B, Lyass L, Lavi S, Bacus SS, et al. Synergistic downregulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy. Proc Natl Acad Sci USA 2005; 102:1915-20. (Pubitemid 40261987)
23. Ben-Kasus T, Schechter B, Lavi S, Yarden Y, Sela M. Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: Relevance of receptor endocytosis. Proc Natl Acad Sci USA 2009; 106:3294-9.
24. Kasprzyk PG, Song SU, Di Fiore PP, King CR. Therapy of an animal model of human gastric cancer using a combination of anti-erbB-2 monoclonal antibodies. Cancer Res 1992; 52:2771-6.
25. Kamat V, Donaldson JM, Kari C, Quadros MR, Lelkes PI, Chaiken I, et al. Enhanced EGFR Inhibition And Distinct Epitope Recognition By EGFR Antagonistic MABS C225 And 425. Cancer Biol Ther 2008; 7:726-33.
26. Perera RM, Narita Y, Furnari FB, Gan HK, Murone C, Ahlkvist M, et al. Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity. Clin Cancer Res 2005; 11:6390-9. (Pubitemid 41262971)
27. Patel D, Guo X, Ng S, Melchior M, Balderes P, Burtrum D, et al. IgG isotype, glycosylation and EGFR expression determine the induction of antibody-dependent cellular cytotoxicity in vitro by cetuximab. Hum Antibodies 2010; 19:89-99.
28. Dechant M, Weisner W, Berger S, Peipp M, Beyer T, Schneider-Merck T, et al. Complement-dependent tumor cell lysis triggered by combinations of epidermal growth factor receptor antibodies. Cancer Res 2008; 68:4998-5003.
29. Cochran JR, Kim YS, Olsen MJ, Bhandari R, Wittrup KD. Domain-level antibody epitope mapping through yeast surface display of epidermal growth factor receptor fragments. J Immunol Methods 2004; 287:147-58. (Pubitemid 38510216)
30. Klonisch T, Panayotou G, Edwards P, Jackson AM, Berger P, Delves PJ, et al. Enhancement in antigen binding by a combination of synergy and antibody capture. Immunology 1996; 89:165-71. (Pubitemid 26340117)
31. Li S, Schmitz KR, Jeffrey PD, Wiltzius JJ, Kussie P, Ferguson KM. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 2005; 7:301-11. (Pubitemid 40544648)
32. Pedersen MW, Jacobsen HJ, Koefoed K, Hey A, Pyke C, Haurum JS, et al. Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy. Cancer Res 2010; 70:588-97.
33. Whitson KB, Whitson SR, Red-Brewer ML, McCoy AJ, Vitali AA, Walker F, et al. Functional effects of glycosylation at Asn-579 of the epidermal growth factor receptor. Biochemistry 2005; 44:14920-31. (Pubitemid 41612271)
34. Overdijk MB, Verploegen S, van den Brakel JH, Lammerts van Bueren JJ, Vink T, Van de Winkel JG, et al. Epidermal Growth Factor Receptor (EGFR) antibody-induced antibody-dependent cellular cytotoxicity plays a prominent role in inhibiting tumorigenesis, even of tumor cells insensitive to EGFR signaling inhibition. J Immunol 2011; [Epub ahead of print]; PMID:21832160; DOI: 10.4049/jimmunol.1003926.
35. Humphrey PA, Gangarosa LM, Wong AJ, Archer GE, Lund-Johansen M, Bjerkvig R, et al. Deletion-mutant epidermal growth factor receptor in human gliomas: effects of type II mutation on receptor function. Biochem Biophys Res Commun 1991; 178:1413-20.
36. Easty DM, Easty GC, Carter RL, Monaghan P, Butler LJ. Ten human carcinoma cell lines derived from squamous carcinomas of the head and neck. Br J Cancer 1981; 43:772-85. (Pubitemid 11071761)
37. Meijer PJ, Andersen PS, Haahr HM, Steinaa L, Jensen A, Lantto J, et al. Isolation of human antibody repertoires with preservation of the natural heavy and light chain pairing. J Mol Biol 2006; 358:764-72.
38. Meijer PJ, Nielsen LS, Lantto J, Jensen A. Human antibody repertoires 2009; 525:261-77.
39. Pedersen MW, Pedersen N, Ottesen LH, Poulsen HS. Differential response to gefitinib of cells expressing normal EGFR and the mutant EGFRvIII. Br J Cancer 2005; 93:915-23. (Pubitemid 41487018)